{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:19:25Z","timestamp":1778152765465,"version":"3.51.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09786-y","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:07:15Z","timestamp":1778152035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of efgartigimod in myasthenia gravis: A meta-analysis of different antibody subtypes"],"prefix":"10.1007","volume":"74","author":[{"given":"Haneen","family":"Sabet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abrar","family":"AbuHamdia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Ahmed","family":"Zanaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"El-Moslemani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia Kamal","family":"Ewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyad","family":"Elyamany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah","family":"Khatatbeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Almarfadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Al-Rayess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gergis","family":"Altalab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed","family":"Aldehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foziah F.","family":"Al-Fawzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. A.","family":"Shaban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"1","key":"9786_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","volume":"19","author":"N Salari","year":"2021","unstructured":"Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, et al. Global prevalence of Myasthenia Gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):516. https:\/\/doi.org\/10.1186\/s12967-021-03185-7.","journal-title":"J Transl Med"},{"issue":"26","key":"9786_CR2","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570\u201381. https:\/\/doi.org\/10.1056\/NEJMra1602678.","journal-title":"N Engl J Med"},{"issue":"5","key":"9786_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/WCO.0b013e328357a829","volume":"25","author":"P Cavalcante","year":"2012","unstructured":"Cavalcante P, Bernasconi P, Mantegazza R. Autoimmune mechanisms in Myasthenia Gravis. Curr Opin Neurol. 2012;25(5):621\u20139. https:\/\/doi.org\/10.1097\/WCO.0b013e328357a829.","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"9786_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/WCO.0b013e328364c079","volume":"26","author":"L Querol","year":"2013","unstructured":"Querol L, Illa I. Myasthenia Gravis and the neuromuscular junction. Curr Opin Neurol. 2013;26(5):459\u201365. https:\/\/doi.org\/10.1097\/WCO.0b013e328364c079.","journal-title":"Curr Opin Neurol"},{"issue":"19","key":"9786_CR5","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.4103\/0366-6999.166032","volume":"128","author":"LL Wang","year":"2015","unstructured":"Wang LL, Zhang Y, He ML. Clinical features and prognosis of ocular Myasthenia Gravis patients with different phenotypes. Chin Med J (Engl). 2015;128(19):2682\u20134. https:\/\/doi.org\/10.4103\/0366-6999.166032.","journal-title":"Chin Med J (Engl)"},{"issue":"27","key":"9786_CR6","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1073\/pnas.0801717105","volume":"105","author":"SW Qiao","year":"2008","unstructured":"Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A. 2008;105(27):9337\u201342. https:\/\/doi.org\/10.1073\/pnas.0801717105.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"9786_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715\u201325. https:\/\/doi.org\/10.1038\/nri2155.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"9786_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","volume":"19","author":"ED Bacci","year":"2019","unstructured":"Bacci ED, Coyne KS, Poon JL, Harris L, Boscoe AN. Understanding side effects of therapy for Myasthenia Gravis and their impact on daily life. BMC Neurol. 2019;19(1):335. https:\/\/doi.org\/10.1186\/s12883-019-1573-2.","journal-title":"BMC Neurol"},{"issue":"6","key":"9786_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. J Clin Med. 2022;11(6):1597. https:\/\/doi.org\/10.3390\/jcm11061597.","journal-title":"J Clin Med"},{"issue":"7","key":"9786_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13071130","volume":"13","author":"A Aggelina","year":"2023","unstructured":"Aggelina A, Karampli E, Mavrovounis G, Boutsikos I, Pantazopoulos I, Kakavas S, et al. Evaluation of the quality of life of patients with myasthenia gravis in Greece. J Pers Med. 2023;13(7):1130. https:\/\/doi.org\/10.3390\/jpm13071130.","journal-title":"J Pers Med"},{"issue":"7","key":"9786_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893\u2013902. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03019.x.","journal-title":"Eur J Neurol"},{"issue":"3","key":"9786_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200276","volume":"14","author":"S Suzuki","year":"2024","unstructured":"Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, Kubota T, et al. Therapeutic responses to Efgartigimod for generalized myasthenia gravis in Japan. Neurol Clin Pract. 2024;14(3):e200276. https:\/\/doi.org\/10.1212\/CPJ.0000000000200276.","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"9786_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207937","volume":"102","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, et al. Safety and efficacy of Nipocalimab in patients with generalized myasthenia gravis. Neurology. 2024;102(2):e207937. https:\/\/doi.org\/10.1212\/WNL.0000000000207937.","journal-title":"Neurology"},{"issue":"2","key":"9786_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","volume":"24","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S, Nowak RJ, Farmakidis C, Bril V, et al. Safety and efficacy of Nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(24)00498-8.","journal-title":"Lancet Neurol"},{"issue":"3","key":"9786_CR15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40120-025-00748-4","volume":"14","author":"M Yoshikawa","year":"2025","unstructured":"Yoshikawa M, Inoue Y, Tanaka K, Tsumura K, Hoshino Y, Shichijo C, et al. Real-world experience with FcRn inhibitors Efgartigimod and Rozanolixizumab in myasthenia gravis: administration in multiple cycles and transition from intravenous to subcutaneous formulation. Neurol Ther. 2025;14(3):977\u201388. https:\/\/doi.org\/10.1007\/s40120-025-00748-4.","journal-title":"Neurol Ther"},{"issue":"7_Supplement_1","key":"9786_CR16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208795","volume":"104","author":"ZK Mahuwala","year":"2025","unstructured":"Mahuwala ZK, Habib AA, Pascuzzi RM, Vissing J, Vu T, Grimson F, et al. Effect of Rozanolixizumab on ocular symptoms in patients with generalized Myasthenia Gravis: a post hoc item-level analysis of Myasthenia Gravis-specific outcomes in MycarinG (P1-11.006). Neurology. 2025;104(7_Supplement_1):1866. https:\/\/doi.org\/10.1212\/WNL.0000000000208795.","journal-title":"Neurology"},{"issue":"7","key":"9786_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"key":"9786_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2025.108910","volume":"254","author":"M Akhtar","year":"2025","unstructured":"Akhtar M, Akhtar M, Farooqi HA, Maryam A, Muzammil A, Hanif U, et al. Efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: an updated systematic review and meta\u2011analysis. Clin Neurol Neurosurg. 2025;254:108910. https:\/\/doi.org\/10.1016\/j.clineuro.2025.108910.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"9786_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-03057-6","volume":"30","author":"JJ Cheng","year":"2025","unstructured":"Cheng JJ, Wang FQ, Dai ZY, Wang XW, Wang Y. The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis. Eur J Med Res. 2025;30(1):775. https:\/\/doi.org\/10.1186\/s40001-025-03057-6.","journal-title":"Eur J Med Res"},{"key":"9786_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110457","volume":"274","author":"C Zhang","year":"2025","unstructured":"Zhang C, Li X, Deng Y, Luo H, Wang S, Yan X, et al. The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients. Clin Immunol. 2025;274:110457. https:\/\/doi.org\/10.1016\/j.clim.2025.110457.","journal-title":"Clin Immunol"},{"issue":"1","key":"9786_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/mus.28003","volume":"69","author":"M Singer","year":"2024","unstructured":"Singer M, Khella S, Bird S, McIntosh P, Paudyal B, Wadhwani A, et al. Single institution experience with efgartigimod in patients with myasthenia gravis: patient selection, dosing schedules, treatment response, and adverse events. Muscle Nerve. 2024;69(1):87\u201392. https:\/\/doi.org\/10.1002\/mus.28003.","journal-title":"Muscle Nerve"},{"issue":"5","key":"9786_CR22","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/mus.27974","volume":"68","author":"N Katyal","year":"2023","unstructured":"Katyal N, Halldorsdottir K, Govindarajan R, Shieh P, Muley S, Reyes P, et al. Safety and outcomes with efgartigimod use for Acetylcholine receptor\u2010positive generalized myasthenia gravis in clinical practice. Muscle Nerve. 2023;68(5):762\u20136. https:\/\/doi.org\/10.1002\/mus.27974.","journal-title":"Muscle Nerve"},{"issue":"5","key":"9786_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/14712598.2025.2490063","volume":"25","author":"H Teranishi","year":"2025","unstructured":"Teranishi H, Tsuda K, Kanzaki R, Hayashi T, Harada D. Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance. Expert Opin Biol Ther. 2025;25(5):543\u201350. https:\/\/doi.org\/10.1080\/14712598.2025.2490063.","journal-title":"Expert Opin Biol Ther"},{"key":"9786_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123652","volume":"477","author":"N Goyal","year":"2025","unstructured":"Goyal N, Qi C, Stone J, Ruck T, Wolfe GI, Smith AG, et al. Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis. J Neurol Sci. 2025;477:123652. https:\/\/doi.org\/10.1016\/j.jns.2025.123652.","journal-title":"J Neurol Sci"},{"key":"9786_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1555068","volume":"16","author":"M Sgarzi","year":"2025","unstructured":"Sgarzi M, Paone P, Camera G, Agazzi E, Mazzoleni S, Martorana F, et al. Real world study in Italian public hospital with efgartigimod in patients affected by generalized myasthenia gravis: influence of clinical and serological factors. Front Neurol. 2025;16:1555068. https:\/\/doi.org\/10.3389\/fneur.2025.1555068.","journal-title":"Front Neurol"},{"issue":"1","key":"9786_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200331","volume":"12","author":"F Stascheit","year":"2025","unstructured":"Stascheit F, Sousa CDFD, Aigner A, Behrens M, Keller CW, Klotz L, et al. Ravulizumab and efgartigimod in myasthenia gravis: a real-world study. Neurol Neuroimmunol Neuroinflamm. 2025;12(1):e200331. https:\/\/doi.org\/10.1212\/NXI.0000000000200331.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"9786_CR27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600","author":"JF Howard","year":"2019","unstructured":"Howard JF, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized Myasthenia Gravis. Neurology. 2019. https:\/\/doi.org\/10.1212\/WNL.0000000000007600.","journal-title":"Neurology"},{"issue":"8","key":"9786_CR28","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.jtho.2025.04.014","volume":"20","author":"S Wang","year":"2025","unstructured":"Wang S, Zhu M, Dong J, Zhang Y, Luo S, Jiang J, et al. Perioperative safety and efficacy of efgartigimod for thymoma-associated myasthenia gravis: a prospective, multicenter, phase II clinical trial. J Thorac Oncol. 2025;20(8):1120\u201330. https:\/\/doi.org\/10.1016\/j.jtho.2025.04.014.","journal-title":"J Thorac Oncol"},{"key":"9786_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251319656","volume":"18","author":"L Jin","year":"2025","unstructured":"Jin L, Zou Z, Wang Q, Zeng W, Jiang Q, Chen J, et al. Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes. Ther Adv Neurol Disord. 2025;18:17562864251319656. https:\/\/doi.org\/10.1177\/17562864251319656.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"9786_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/mus.28334","volume":"71","author":"NJ Silvestri","year":"2025","unstructured":"Silvestri NJ. Individualized dosing of efgartigimod in patients with generalized myasthenia gravis: clinical experience at a single center. Muscle Nerve. 2025;71(3):422\u20138. https:\/\/doi.org\/10.1002\/mus.28334.","journal-title":"Muscle Nerve"},{"issue":"1","key":"9786_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-025-04063-1","volume":"25","author":"F Shi","year":"2025","unstructured":"Shi F, Lai R, Feng L, Zhou H, Sun X, Shen C, et al. Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neuro intensive care unit. BMC Neurol. 2025;25(1):79. https:\/\/doi.org\/10.1186\/s12883-025-04063-1.","journal-title":"BMC Neurol"},{"issue":"1","key":"9786_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12883-025-04063-1","volume":"25","author":"F Shi","year":"2025","unstructured":"Shi F, Lai R, Feng L, Zhou H, Sun X, Shen C, et al. Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neonatal intensive care unit. BMC Neurol. 2025;25(1):79. https:\/\/doi.org\/10.1186\/s12883-025-04063-1.","journal-title":"BMC Neurol"},{"key":"9786_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110587","volume":"281","author":"D He","year":"2025","unstructured":"He D, Jin L, Wang S, Zhong H, Chen H, Zhou H, et al. Efgartigimod versus standard of care in new-onset AChR subtype generalized myasthenia gravis: a prospective cohort study. Clin Immunol. 2025;281:110587. https:\/\/doi.org\/10.1016\/j.clim.2025.110587.","journal-title":"Clin Immunol"},{"key":"9786_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251326778","volume":"18","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Zhou Q, Yue Y, Luo S, Song J, Yan C, et al. Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis. Ther Adv Neurol Disord. 2025;18:17562864251326778. https:\/\/doi.org\/10.1177\/17562864251326778.","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"9786_CR35","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W, Wang Q, Zou Z, Yu Y, et al. Efgartigimod for generalized myasthenia gravis: a multicenter real\u2010world cohort study in China. Ann Clin Transl Neurol. 2024;11(8):2212\u201321. https:\/\/doi.org\/10.1002\/acn3.52142.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"9786_CR36","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/jnnp-2024-334086","volume":"96","author":"J Moniz Dion\u00edsio","year":"2025","unstructured":"Moniz Dion\u00edsio J, Ambrose P, Burke G, Farrugia ME, Garcia-Reitboeck P, Hewamadduma C, et al. Efgartigimod efficacy and safety in refractory myasthenia gravis: UK\u2019s first real-world experience. J Neurol Neurosurg Psychiatry. 2025;96(4):322\u20138. https:\/\/doi.org\/10.1136\/jnnp-2024-334086.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9786_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114603","volume":"154","author":"J Chen","year":"2025","unstructured":"Chen J, Zhu X, Zhou H, Huang W, Wu W, Chen C, et al. Efficacy of multi-cycle Efgartigimod in achieving minimal symptom expression in myasthenia gravis: a comparative multi-center study. Int Immunopharmacol. 2025;154:114603. https:\/\/doi.org\/10.1016\/j.intimp.2025.114603.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"9786_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70391","volume":"31","author":"S Hao","year":"2025","unstructured":"Hao S, Ruan Z, Guo R, Wang Q, Huang X, Sun C, et al. Efficacy and safety of Efgartigimod for patients with myasthenia gravis in a real\u2010world cohort of 77 patients. CNS Neurosci Ther. 2025;31(4):e70391. https:\/\/doi.org\/10.1111\/cns.70391.","journal-title":"CNS Neurosci Ther"},{"key":"9786_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241311127","volume":"18","author":"G Zhu","year":"2025","unstructured":"Zhu G, Zhou H, Wang W, Ma Y, Nie X, Qi W, et al. Application of Efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study. Ther Adv Neurol Disord. 2025;18:17562864241311127. https:\/\/doi.org\/10.1177\/17562864241311127.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"9786_CR40","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/acn3.70051","volume":"12","author":"AA Habib","year":"2025","unstructured":"Habib AA, Claeys KG, Bril V, Hussain Y, Gwathmey K, Sahagian G, et al. ADAPT NXT\u202f: fixed cycles or every\u2010other\u2010week IV Efgartigimod in generalized myasthenia gravis. Ann Clin Transl Neurol. 2025;12(6):1162\u201370. https:\/\/doi.org\/10.1002\/acn3.70051.","journal-title":"Ann Clin Transl Neurol"},{"key":"9786_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"8","key":"9786_CR42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","volume":"156","author":"BS Brooke","year":"2021","unstructured":"Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156(8):787\u20138. https:\/\/doi.org\/10.1001\/jamasurg.2021.0522.","journal-title":"JAMA Surg"},{"key":"9786_CR43","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 2024 Sep 2]. Available from: https:\/\/training.cochrane.org\/handbook"},{"key":"9786_CR44","unstructured":"Borenstein M, editor. Introduction to meta-analysis. Nachdr. Chichester: Wiley; 2013. 421 p."},{"issue":"1","key":"9786_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"9786_CR46","unstructured":"Free Online Spreadsheet Software: Excel | Microsoft 365 [Internet]. [cited 2024 Dec 4]. Available from: https:\/\/www.microsoft.com\/en-us\/microsoft-365\/excel"},{"issue":"7","key":"9786_CR47","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139. https:\/\/doi.org\/10.1212\/wnl.52.7.1487.","journal-title":"Neurology"},{"key":"9786_CR48","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769\u201372. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb11015.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"9786_CR49","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","volume":"54","author":"TM Burns","year":"2016","unstructured":"Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, et al. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016;54(6):1015\u201322. https:\/\/doi.org\/10.1002\/mus.25198.","journal-title":"Muscle Nerve"},{"key":"9786_CR50","unstructured":"ResearchGate [Internet]. [cited 2025 Jun 14]. The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis | Request PDF. Available from: https:\/\/www.researchgate.net\/publication\/261773681_The_Newcastle-Ottawa_Scale_NOS_for_Assessing_the_Quality_of_Non-Randomized_Studies_in_Meta-Analysis"},{"key":"9786_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"9786_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"9786_CR53","unstructured":"R: The R Project for Statistical Computing [Internet]. [cited 2025 Nov 14]. Available from: https:\/\/www.r-project.org\/"},{"key":"9786_CR54","unstructured":"27. Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020."},{"key":"9786_CR55","unstructured":"9.5.2 Identifying and measuring heterogeneity [Internet]. [cited 2024 Sep 3]. Available from: https:\/\/handbook-5-1.cochrane.org\/chapter_9\/9_5_2_identifying_and_measuring_heterogeneity.htm"},{"issue":"7109","key":"9786_CR56","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"2","key":"9786_CR57","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341x.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455\u201363. https:\/\/doi.org\/10.1111\/j.0006-341x.2000.00455.x.","journal-title":"Biometrics"},{"issue":"1","key":"9786_CR58","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A. Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol. 2024;24(1):243. https:\/\/doi.org\/10.1186\/s12874-024-02356-6.","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"9786_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00378","volume":"21","author":"JF Howard","year":"2024","unstructured":"Howard JF, Vu T, Li G, Korobko D, Smilowski M, Liu L, et al. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). Neurotherapeutics. 2024;21(5):e00378. https:\/\/doi.org\/10.1016\/j.neurot.2024.e00378.","journal-title":"Neurotherapeutics"},{"issue":"7","key":"9786_CR60","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"key":"9786_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1407418","volume":"15","author":"P Wang","year":"2024","unstructured":"Wang P, Zhang B, Yin J, Xi J, Tan Y, Gao F, et al. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients. Front Neurol. 2024;15:1407418. https:\/\/doi.org\/10.3389\/fneur.2024.1407418.","journal-title":"Front Neurol"},{"key":"9786_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1486659","volume":"15","author":"F Shi","year":"2024","unstructured":"Shi F, Chen J, Feng L, Lai R, Zhou H, Sun X, et al. Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation. Front Neurol. 2024;15:1486659. https:\/\/doi.org\/10.3389\/fneur.2024.1486659.","journal-title":"Front Neurol"},{"issue":"3","key":"9786_CR63","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/mus.28184","volume":"70","author":"L Remijn\u2010Nelissen","year":"2024","unstructured":"Remijn\u2010Nelissen L, Tannemaat MR, Ruiter AM, Campman YJM, Verschuuren JJGM. Efgartigimod in refractory autoimmune myasthenia gravis. Muscle Nerve. 2024;70(3):325\u201332. https:\/\/doi.org\/10.1002\/mus.28184.","journal-title":"Muscle Nerve"},{"issue":"4","key":"9786_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16189","volume":"31","author":"R Frangiamore","year":"2024","unstructured":"Frangiamore R, Rinaldi E, Vanoli F, Andreetta F, Ciusani E, Bonanno S, et al. Efgartigimod in generalized myasthenia gravis: a real\u2010life experience at a national reference center. Eur J Neurol. 2024;31(4):e16189. https:\/\/doi.org\/10.1111\/ene.16189.","journal-title":"Eur J Neurol"},{"issue":"9","key":"9786_CR65","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","volume":"271","author":"C Pane","year":"2024","unstructured":"Pane C, Di Stefano V, Cuomo N, Sarnataro A, Vinciguerra C, Bevilacqua L, et al. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol. 2024;271(9):6209\u201319. https:\/\/doi.org\/10.1007\/s00415-024-12588-7.","journal-title":"J Neurol"},{"issue":"3","key":"9786_CR66","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Efgartigimod: first approval. Drugs. 2022;82(3):341\u20138. https:\/\/doi.org\/10.1007\/s40265-022-01678-3.","journal-title":"Drugs"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09786-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09786-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09786-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:07:21Z","timestamp":1778152041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09786-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9786"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09786-y","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We confirm that this manuscript complies with all instructions to authors, that all authors meet the authorship criteria and have approved the final version of the manuscript, and the PRISMA checklist was used.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"We declare that this study has not been published at all.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous publication"}},{"value":"We declare that we have not used AI in writing any part of this abstract.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI in scientific writing"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"53"}}